@FierceMedDev: Boston Sci is one step closer to getting Watchman, for irregular heartbeat, on the U.S. market. Item | Follow @FierceMedDev
@MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce
@DamianFierce: In his first year as CEO of Medtronic, Omar Ishrak took home a healthy $25M. Story | Follow @DamianFierce
> NPR's "Morning Edition" checked in with devicemakers as they prepare for the impending 2.3% tax, checking in with smaller devicemakers who fear the charge could put them out of business. Listen
> The FDA has granted Edwards Lifesciences ($EW) an investigational device exemption to start trials on its Intuity heart valve. News
> Speaking of the device tax, one analyst says that Baxter ($BAX) will likely suffer little from the charge, while Boston Scientific ($BSX) is the "most exposed" devicemaker. Article
> Diagnostic firm Great Basin's molecular-based tuberculosis test has demonstrated 96% accuracy in detecting a treatment-resistant form of the disease. Release
> Masimo ($MASI) has signed a distribution deal with PSS World Medical, getting the company's Pronto-7 handheld hemoglobin checker into the hands of physicians nationwide. More
Pharma News
@FiercePharma: Glaxo will be our new No. 1 in the Top 10 Pharma Settlements special report. More | Follow @FiercePharma
> Icahn crony could profit off a seat on Forest board. Story
> GSK's Zofran arrhythmia risk leads to new label change. Item
> Bristol-Myers, AZ aim for diabetes glory with Amylin buy. News
> GSK pays $3B to wrap up host of Justice Department claims. Article
Biotech News
@FierceBiotech: Which biotech will be the next to get swept away in the M&A wave? More | Follow @FierceBiotech
@JohnCFierce: Bloomberg counts 5 $1B-plus buyouts so far this year, trending up. Also, some data I've seen suggests licensing $$ shrinking. More | Follow @JohnCFierce
@RyanMFierce: Google's new cloud platform attracts biotech players, could rival Amazon EC2 in pharma. More | Follow @RyanMFierce
> Bristol-Myers outbids Big Pharma pack and nabs Amylin for $5.3B. Story
> Which biotech will be the next to get swept away in the M&A wave? Article
> GSK, Theravance race rivals with PhIII COPD data on LAMA/LABA combo. News
> Icahn confederate could profit off a seat on Forest board. Item
Biotech IT News
> Boehringer claims 'gamification' win in pharma. News
> Microsoft honors Bristol-Myers, Novartis and Sanofi. Article
> Pfizer boosts online offerings to German docs. Item